Pharma corporations have discreetly raised prices on dozens of Pharma behind the scenes as drug pricing debates resurface in Washington, D.C. According to GoodRx’s calculations, Pharma companies large and small have raised prices on 65 medications, essentially brand names, by an average of 3.5 percent this month. That’s more than double the number from only two weeks ago and only a few hundred short of the July 2020 total.
While smaller drugmakers specializing in rare ailments led the early price hikes to begin the month, Pfizer, Eli Lilly, Sanofi, AstraZeneca, Bristol Myers Squibb, Novartis, and AbbVie have also joined in on the action. The majority of the price increases are in the single digits. Sanofi and Bristol, for example, increased the pricing of four drugs by 1.5 percent to 2.5 percent each, including a slight increase in the price of Bristol’s blockbuster checkpoint inhibitor Opdivo.
That treatment has surpassed Zogenix’s 9.5 percent gain for Fintepla, a rare childhood epilepsy drug, which is now in second place. Acadia Pharma‘ Nuplazid, which is used to treat Parkinson’s-related hallucinations and delusions, is not far behind. Jazz Pharma, which is further down the list, increased the price of two of its medications, Zepzelca and Defitelio, by 4% and 3%, respectively.